Pharaoh Neuro, Inc.

Pharaoh Neuro, Inc. is a US-based company focused on developing advanced medical technologies that enhance neurocritical care through innovative products, particularly the Neurapheresis™ platform. Founded by Rich Nazarian, Mark Wagner, and Dr. Nandan Lad, Pharaoh Neuro, Inc.

specializes in neurocritical care technologies and has its headquarters in Minneapolis, US. The company has secured funding in February 2026 through a Series A round, raising USD 20. 00 mn led by Arboretum Ventures, with participation from Hatteras Venture Partners, IAG Capital Partners, and Laerdal Million Lives Fund. The current CEO is Amaza Reitmeier.

Pharaoh Neuro specializes in pioneering medical technologies aimed at enhancing neurocritical care through its flagship product, the Neurapheresis™ platform. This innovative system is designed for the precision management of cerebrospinal fluid (CSF), addressing critical medical needs in patients with neurocritical conditions such as aneurysmal subarachnoid hemorrhage. The Neurapheresis™ technology focuses on stabilizing CSF balance, essential for maintaining brain health. The primary users of these products include neurocritical care units in hospitals, neurosurgeons, and other healthcare professionals specialized in treating severe neurological disorders.

The company is actively looking to expand its reach in North America and Europe, with products being utilized in advanced medical facilities emphasizing neurological health care. The company will use the funding to support the development and regulatory clearance of its Neurapheresis cerebrospinal fluid management system and to reintroduce its MindsEye cranial access device in the U. S. market.

The company aims to expand into North America and Europe, leveraging this funding to enhance its product offerings and market presence.